Event submissions
Published
10.3390/ECMC2023-15689 (registering DOI) This submission belongs to the session S5. Natural Products and Biopharmaceuticals of the event 9th International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2023
Academic Editor
'%3e%3cpath%20d='M12.6657%2010.9104C12.4185%2010.325%2012.0599%209.79327%2011.6097%209.34482C11.1609%208.89508%2010.6293%208.5365%2010.0442%208.28888C10.0389%208.28626%2010.0337%208.28495%2010.0285%208.28233C10.8446%207.69279%2011.3752%206.73249%2011.3752%205.64904C11.3752%203.8542%209.92103%202.39999%208.1262%202.39999C6.33136%202.39999%204.87715%203.8542%204.87715%205.64904C4.87715%206.73249%205.40774%207.69279%206.22393%208.28364C6.21869%208.28626%206.21345%208.28757%206.20821%208.29019C5.62129%208.5378%205.09463%208.89284%204.64265%209.34613C4.1929%209.79493%203.83432%2010.3266%203.58671%2010.9117C3.34345%2011.4845%203.21226%2012.0987%203.20023%2012.7209C3.19988%2012.7349%203.20233%2012.7488%203.20744%2012.7619C3.21255%2012.7749%203.22022%2012.7867%203.22998%2012.7968C3.23975%2012.8068%203.25142%2012.8147%203.26431%2012.8202C3.2772%2012.8256%203.29105%2012.8284%203.30504%2012.8284H4.09109C4.14874%2012.8284%204.19459%2012.7825%204.1959%2012.7262C4.2221%2011.7148%204.62823%2010.7676%205.34617%2010.0497C6.08899%209.30683%207.0755%208.89808%208.1262%208.89808C9.17689%208.89808%2010.1634%209.30683%2010.9062%2010.0497C11.6242%2010.7676%2012.0303%2011.7148%2012.0565%2012.7262C12.0578%2012.7838%2012.1037%2012.8284%2012.1613%2012.8284H12.9474C12.9613%2012.8284%2012.9752%2012.8256%2012.9881%2012.8202C13.001%2012.8147%2013.0126%2012.8068%2013.0224%2012.7968C13.0322%2012.7867%2013.0398%2012.7749%2013.0449%2012.7619C13.0501%2012.7488%2013.0525%2012.7349%2013.0522%2012.7209C13.0391%2012.0947%2012.9094%2011.4855%2012.6657%2010.9104ZM8.1262%207.9024C7.52486%207.9024%206.9589%207.6679%206.53312%207.24211C6.10733%206.81633%205.87283%206.25037%205.87283%205.64904C5.87283%205.0477%206.10733%204.48174%206.53312%204.05596C6.9589%203.63018%207.52486%203.39567%208.1262%203.39567C8.72753%203.39567%209.29349%203.63018%209.71927%204.05596C10.1451%204.48174%2010.3796%205.0477%2010.3796%205.64904C10.3796%206.25037%2010.1451%206.81633%209.71927%207.24211C9.29349%207.6679%208.72753%207.9024%208.1262%207.9024Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Maria Emília SousaCitation
Dzerassa Gurtsieva, Ekaterina Minskaia, Sofia Zhuravleva, Alexander Karabelsky, Engineered AAV2.7m8 serotype shows significantly higher transduction efficiency of ARPE-19 and HEK293 cell lines compared to AAV2/5, 2/8 and 2/9 serotypes, in Proceedings of 9th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2023, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2023-15689
Share
Email
Facebook
Twitter
LinkedIn
Engineered AAV2.7m8 serotype shows significantly higher transduction efficiency of ARPE-19 and HEK293 cell lines compared to AAV2/5, 2/8 and 2/9 serotypes
'%3e%3cpath%20d='M12.6647%2010.9104C12.4176%2010.325%2012.0589%209.7933%2011.6088%209.34485C11.16%208.89511%2010.6283%208.53653%2010.0432%208.28891C10.038%208.28629%2010.0327%208.28498%2010.0275%208.28236C10.8437%207.69282%2011.3743%206.73252%2011.3743%205.64907C11.3743%203.85423%209.92005%202.40002%208.12522%202.40002C6.33038%202.40002%204.87618%203.85423%204.87618%205.64907C4.87618%206.73252%205.40677%207.69282%206.22296%208.28367C6.21772%208.28629%206.21248%208.2876%206.20724%208.29022C5.62031%208.53783%205.09365%208.89287%204.64167%209.34616C4.19192%209.79496%203.83334%2010.3266%203.58573%2010.9117C3.34247%2011.4846%203.21128%2012.0987%203.19925%2012.721C3.1989%2012.735%203.20135%2012.7489%203.20646%2012.7619C3.21157%2012.7749%203.21924%2012.7868%203.22901%2012.7968C3.23877%2012.8068%203.25045%2012.8148%203.26334%2012.8202C3.27623%2012.8256%203.29007%2012.8284%203.30406%2012.8284H4.09012C4.14776%2012.8284%204.19362%2012.7825%204.19493%2012.7262C4.22113%2011.7148%204.62726%2010.7676%205.34519%2010.0497C6.08802%209.30686%207.07452%208.89811%208.12522%208.89811C9.17592%208.89811%2010.1624%209.30686%2010.9052%2010.0497C11.6232%2010.7676%2012.0293%2011.7148%2012.0555%2012.7262C12.0568%2012.7839%2012.1027%2012.8284%2012.1603%2012.8284H12.9464C12.9604%2012.8284%2012.9742%2012.8256%2012.9871%2012.8202C13%2012.8148%2013.0117%2012.8068%2013.0214%2012.7968C13.0312%2012.7868%2013.0389%2012.7749%2013.044%2012.7619C13.0491%2012.7489%2013.0515%2012.735%2013.0512%2012.721C13.0381%2012.0947%2012.9084%2011.4856%2012.6647%2010.9104ZM8.12522%207.90243C7.52388%207.90243%206.95792%207.66793%206.53214%207.24215C6.10636%206.81636%205.87185%206.2504%205.87185%205.64907C5.87185%205.04773%206.10636%204.48177%206.53214%204.05599C6.95792%203.63021%207.52388%203.3957%208.12522%203.3957C8.72655%203.3957%209.29252%203.63021%209.7183%204.05599C10.1441%204.48177%2010.3786%205.04773%2010.3786%205.64907C10.3786%206.2504%2010.1441%206.81636%209.7183%207.24215C9.29252%207.66793%208.72655%207.90243%208.12522%207.90243Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Dzerassa Gurtsieva 1
Ekaterina Minskaia 1
Sofia Zhuravleva 1
Alexander Karabelsky 1
1. Sirius University of Science and Technology, Sochi, Russia
Abstract
Keywords
gene therapy
AAV
IRD
ARPE-19
transduction
efficiency
retina
serotype
AAV2.7m8
RDH12
Manuscript
9th-ECMC_Poster final EM 17okt23.pdf
Poster
9th-ECMC_Poster final EM 17okt23.pdf